FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3000612013> ?p ?o ?g. }

• W3000612013 endingPage "ixe9" @default.
• W3000612013 startingPage "ixe9" @default.
• W3000612013 abstract "ABSTRACT Background The potential benefit of adding CTX to the current standard treatment for stage III CC, was assessed. Subgroup analyses of demographic, oncologic and molecular data may improve our understanding of this patient population. Methods CC pts were randomized 28-56 days following resection. They received 12 biweekly cycles of oxaliplatin 85 mg/m2 day (d) 1, with leucovorin 200 mg/m2, 5-FU 400 mg/m2 bolus IV, followed by 5-FU 600 mg/m2 22-hr IV on d1-2 (FOLFOX4), without (arm A) or with weekly CTX (arm B) 250 mg/m2 (initial dose 400 mg/m2, cycle 1). Primary endpoint was disease free survival time (DFS). Secondary endpoints included overall survival (OS), treatment compliance and safety. Planned accrual of 1,407 KRAS wild-type (wt) pts provided 90% power to detect a hazard ratio (HR) of 0.75 with 2-sided a = 0.05, with interim analyses after 65% of planned events. Preplanned subgroup analyses were performed. Results 1,602 KRAS wt pts (811 arm A, 791 arm B), were randomized. BRAF status was determined in 1134 (71%) KRAS wt pts; median follow-up ∼40 months. This interim analysis showed no difference between arms for DFS (HR 1.047, 95% CI 0.85, 1.29; p = 0.66) or OS (HR 1.09, 95% CI 0.81, 1.46; p = 0.55) in KRAS wt pts or for DFS (HR 0.985, 95% CI 0.75, 1.28; p = 0.91) or OS (HR 0.98, 95% CI 0.67, 1.44; p = 0.92) in KRAS/BRAF wt pts (n = 984). Worse outcomes were seen with CTX in pts >70 years (n = 149, DFS: HR 1.97, 95% CI 0.99, 3.93; p = 0.051), in females (n = 666, HR 1.45, 95% CI 1.03, 2.02; p = 0.03) and pts with right-sided CC (n = 570, HR 1.40, 95% CI 1.01, 1.94; p = 0.04). Conversely, a trend towards a better outcome was seen in pts with poor prognosis tumors (high grade, T4, N2, perforation/obstruction, VELI+) and was significant in pts with pT4N2 at diagnosis (n = 146, HR 0.55, 95% CI 0.35-0.88; p = 0.01). Conclusions In this trial adding CTX to FOLFOX4 offered no benefit to pts with resected stage III KRAS wt and KRAS/BRAF wt CC. Subgroup analyses in this large population suggest that pts with pT4N2 tumors may receive some benefit from CTX in this setting. MSI status determination is ongoing to explore its interaction with poor outcome in female pts and those with right-sided tumors. Supported by Merck-Serono, Sanofi-Aventis. Disclosure J. Tabernero: Participated at a Merck KGaA board G. Folprecht: -Honoraries, for lectures and advisory boards from Merck KGaA and Bristol Mayers Squibb. -Study grant from Merck KGaA -Involved in clinical trials with Imclone and Merck KGaA E.J.D. Van Cutsem: Eric Van Cutsem received research funding from Merckserono. P. Rougier: Consultancy/advisory role and honoraria Merck KGaA. O. Bouche: Membership on an advisory board P. Laurent-Puig: Membership on an advisory board of Merck Serono and Amgen. All other authors have declared no conflicts of interest." @default.
• W3000612013 created "2020-01-23" @default.
• W3000612013 creator A5006486870 @default.
• W3000612013 creator A5012667192 @default.
• W3000612013 creator A5012784092 @default.
• W3000612013 creator A5015509025 @default.
• W3000612013 creator A5024180743 @default.
• W3000612013 creator A5028827732 @default.
• W3000612013 creator A5036350507 @default.
• W3000612013 creator A5038016963 @default.
• W3000612013 creator A5038282534 @default.
• W3000612013 creator A5039285562 @default.
• W3000612013 creator A5042372248 @default.
• W3000612013 creator A5046556336 @default.
• W3000612013 creator A5057430651 @default.
• W3000612013 creator A5059137296 @default.
• W3000612013 creator A5070179654 @default.
• W3000612013 creator A5077000250 @default.
• W3000612013 creator A5083765215 @default.
• W3000612013 creator A5083898918 @default.
• W3000612013 creator A5083899904 @default.
• W3000612013 date "2012-09-01" @default.
• W3000612013 modified "2023-10-18" @default.
• W3000612013 title "Adjuvant Folfox4 with or without Cetuximab (CTX) in Patients (PTS) with Resected Stage III Colon Cancer (CC): Dfs and OS Results and Subgroup Analyses of the PETACC8 Intergroup Phase III Trial" @default.
• W3000612013 doi "https://doi.org/10.1016/s0923-7534(20)34317-9" @default.
• W3000612013 hasPublicationYear "2012" @default.
• W3000612013 type Work @default.
• W3000612013 sameAs 3000612013 @default.
• W3000612013 citedByCount "7" @default.
• W3000612013 countsByYear W30006120132013 @default.
• W3000612013 countsByYear W30006120132014 @default.
• W3000612013 countsByYear W30006120132015 @default.
• W3000612013 countsByYear W30006120132016 @default.
• W3000612013 countsByYear W30006120132020 @default.
• W3000612013 crossrefType "journal-article" @default.
• W3000612013 hasAuthorship W3000612013A5006486870 @default.
• W3000612013 hasAuthorship W3000612013A5012667192 @default.
• W3000612013 hasAuthorship W3000612013A5012784092 @default.
• W3000612013 hasAuthorship W3000612013A5015509025 @default.
• W3000612013 hasAuthorship W3000612013A5024180743 @default.
• W3000612013 hasAuthorship W3000612013A5028827732 @default.
• W3000612013 hasAuthorship W3000612013A5036350507 @default.
• W3000612013 hasAuthorship W3000612013A5038016963 @default.
• W3000612013 hasAuthorship W3000612013A5038282534 @default.
• W3000612013 hasAuthorship W3000612013A5039285562 @default.
• W3000612013 hasAuthorship W3000612013A5042372248 @default.
• W3000612013 hasAuthorship W3000612013A5046556336 @default.
• W3000612013 hasAuthorship W3000612013A5057430651 @default.
• W3000612013 hasAuthorship W3000612013A5059137296 @default.
• W3000612013 hasAuthorship W3000612013A5070179654 @default.
• W3000612013 hasAuthorship W3000612013A5077000250 @default.
• W3000612013 hasAuthorship W3000612013A5083765215 @default.
• W3000612013 hasAuthorship W3000612013A5083898918 @default.
• W3000612013 hasAuthorship W3000612013A5083899904 @default.
• W3000612013 hasBestOaLocation W30006120131 @default.
• W3000612013 hasConcept C121608353 @default.
• W3000612013 hasConcept C126322002 @default.
• W3000612013 hasConcept C143998085 @default.
• W3000612013 hasConcept C146357865 @default.
• W3000612013 hasConcept C151730666 @default.
• W3000612013 hasConcept C187960798 @default.
• W3000612013 hasConcept C2777863537 @default.
• W3000612013 hasConcept C2779998722 @default.
• W3000612013 hasConcept C526805850 @default.
• W3000612013 hasConcept C71924100 @default.
• W3000612013 hasConcept C86803240 @default.
• W3000612013 hasConcept C95190672 @default.
• W3000612013 hasConceptScore W3000612013C121608353 @default.
• W3000612013 hasConceptScore W3000612013C126322002 @default.
• W3000612013 hasConceptScore W3000612013C143998085 @default.
• W3000612013 hasConceptScore W3000612013C146357865 @default.
• W3000612013 hasConceptScore W3000612013C151730666 @default.
• W3000612013 hasConceptScore W3000612013C187960798 @default.
• W3000612013 hasConceptScore W3000612013C2777863537 @default.
• W3000612013 hasConceptScore W3000612013C2779998722 @default.
• W3000612013 hasConceptScore W3000612013C526805850 @default.
• W3000612013 hasConceptScore W3000612013C71924100 @default.
• W3000612013 hasConceptScore W3000612013C86803240 @default.
• W3000612013 hasConceptScore W3000612013C95190672 @default.
• W3000612013 hasLocation W30006120131 @default.
• W3000612013 hasOpenAccess W3000612013 @default.
• W3000612013 hasPrimaryLocation W30006120131 @default.
• W3000612013 hasRelatedWork W1908989187 @default.
• W3000612013 hasRelatedWork W2049754458 @default.
• W3000612013 hasRelatedWork W2313360580 @default.
• W3000612013 hasRelatedWork W2435704186 @default.
• W3000612013 hasRelatedWork W2439403919 @default.
• W3000612013 hasRelatedWork W2588306759 @default.
• W3000612013 hasRelatedWork W2589204743 @default.
• W3000612013 hasRelatedWork W2944268665 @default.
• W3000612013 hasRelatedWork W3026015583 @default.
• W3000612013 hasRelatedWork W4283782544 @default.
• W3000612013 hasVolume "23" @default.
• W3000612013 isParatext "false" @default.
• W3000612013 isRetracted "false" @default.
• W3000612013 magId "3000612013" @default.
• W3000612013 workType "article" @default.